Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Amino acid injection (17AA-II) is a specialized parenteral nutrition formulation developed by Tianjin Pharmaceutical Research Institute for the management of renal insufficiency. It contains a specific ratio of 17 amino acids, including essential and non-essential amino acids, tailored to meet the nutritional needs of patients with impaired kidney function while minimizing the accumulation of nitrogenous waste. In clinical trials, it has been evaluated in combination with a low-protein diet to improve nutritional status and potentially slow the progression of renal failure compared to standard amino acid formulations like 9AA. The formulation is designed to provide necessary substrates for protein synthesis while reducing the metabolic burden on the kidneys.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on amino acid injection (17AA-II).